Harvard Bioscience (HBIO) delivered earnings and revenue surprises of 0% and 4.92%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Mettler-Toledo's (MTD) first-quarter performance is likely to reflect the adverse impacts of macroeconomic headwinds, and weak momentum across the Industrial and Laboratory segments.
Beyond analysts' top -and-bottom-line estimates for Mettler-Toledo (MTD), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.